Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00691015 · OUTCOME

Overall Survival.

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant · Source last updated 2017-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
At 2 years after PBSCT

Groups in this outcome

All Participants

All regimens were analyzed together.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Participants47

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Participants57.4Not reported44.973.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        44.9
        upper Limit
        73.5
        value
        57.4
denoms
  1. counts
    1. group Id
      OG000
      value
      47
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    All regimens were analyzed together.
    id
    OG000
    title
    All Participants
param Type
NUMBER
reporting Status
POSTED
time Frame
At 2 years after PBSCT
title
Overall Survival.
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice